Gestational Diabetes
Gestational diabetes is a condition characterized by high blood sugar levels that develop during pregnancy, typically in the second trimester, due to insulin resistance. While it often presents few symptoms, it can increase the risk of complications such as pre-eclampsia, need for a Caesarean section, and various health issues for the baby, both immediately after birth and later in life.
Health Outcomes
- Absence of Adverse Pregnancy Complications
- Changed Maternal Plasma Fatty Acids
- Characterized Carbohydrate Metabolism Enzyme Activity
- Diabetes Progression
- Distinct Metabolic Profile
- Improved Apgar Score at 1 Minute
- Improved Beta-Cell Function
- Improved Blood Glucose Concentration
- Improved Blood Glucose Control
- Improved Blood Glucose Levels
- Improved Exclusive Breastfeeding Rate
- Improved Glycemic Control
- Improved Glycemic Response
- Improved HOMA-B
- Improved HbA1c
- Improved Insulin Levels
- Improved Insulin Response
- Improved Insulin Secretion
- Improved Insulin Secretion Rate
- Improved Maternal Health
- Improved Maternal Metabolic Health
- Improved Metabolic Health
- Improved Metabolic Homeostasis
- Improved Metabolic Indicator
- Improved Metabolic Marker
- Improved Perinatal Safety
- Improved Physiological Status in Offspring
- Improved Pregnancy Outcome
- Improved Pregnancy-Related Wellbeing
- Improved SHBG Level
- Improved Safety in Pregnant Women
- Improved Time in Range
- Increased Birth Head Circumference
- Increased Birth Length
- Increased Birth Weight
- Increased Birthweight
- Increased Blood Glucose Levels
- Increased C-peptide Level
- Increased Fasting Insulin Level
- Increased Fetal Head Circumference
- Increased GLP-1 Levels
- Increased Gestational Age
- Increased Gestational Age at Delivery
- Increased Glucagon Level
- Increased Glucagon-Like Peptide 1 Level
- Increased Glucose Uptake
- Increased Glucose Utilization During Feed Restriction
- Increased Growth in Newborns
- Increased Infant Birthweight
- Increased Infant Weight
- Increased Insulin Resistance Level
- Increased Maternal Weight Gain During Pregnancy
- Increased Milk Component Concentrations
- Increased Neonatal Birth Length
- Increased Newborn Weight
- Increased PGDH Expression in Female Placentae
- Increased Preeclampsia Risk
- Increased Proportion with Normalized Hemoglobin A1c
- Increased Reversion to Normoglycemia
- Increased Serum Insulin Levels
- Increased Time in Range
- Influence on Infant Weight
- Maintained Glucose Control
- Modified Fetal Brain Metabolism
- No Adverse Events from Supplementation
- No Change in Metabolic Health
- No Improvement in Adverse Pregnancy Outcomes
- Normal Pregnancy Outcomes
- Preserved Pancreatic Beta-Cell Function
- Prolonged Gestation
- Prolonged Pregnancy Duration
- Reduced 2-Hour Post-OGTT Glucose Level
- Reduced 2-Hour Postprandial Blood Glucose
- Reduced Alpha-cell Expansion
- Reduced Beta Cell Function
- Reduced Diabetes Incidence
- Reduced Diabetes Mellitus Development
- Reduced Fasting Blood Glucose
- Reduced Fasting Blood Glucose Level
- Reduced Fetal Complication
- Reduced Fetal Loss
- Reduced First Phase Insulin Secretion
- Reduced Glucose Area Under the Curve
- Reduced Glucose Tolerance
- Reduced Glycaemic Index
- Reduced Glycated Hemoglobin
- Reduced Glycated Hemoglobin A1c Level
- Reduced Glycated Hemoglobin Level
- Reduced Glycemic Control
- Reduced Glycemic Enzyme Inhibition
- Reduced Glycemic Index
- Reduced Glycemic Parameter
- Reduced Glycemic Response
- Reduced Glycemic Variability
- Reduced Glycosuria
- Reduced HOMA-B
- Reduced HOMA-IR
- Reduced HOMA-β
- Reduced HbA1c Level
- Reduced Homeostasis Model Assessment Index
- Reduced Homeostatic Model Assessment-Insulin Resistance Index
- Reduced Incidence of Type 2 Diabetes
- Reduced Insulin Output (90-min)
- Reduced Intrauterine Fetal Demise
- Reduced Maternal Complication
- Reduced Maternal Mortality
- Reduced Maternal and Neonatal Composite Outcome
- Reduced Maternal-Fetal Complications
- Reduced Metabolic Dysregulation
- Reduced NICU Requirement
- Reduced Neonatal Complication
- Reduced Neonatal Death
- Reduced Neonatal Hypoglycemia
- Reduced Neonatal Risk
- Reduced Peak Plasma Glucose Level
- Reduced Perinatal Loss
- Reduced Perinatal Mortality
- Reduced Postpartum Hemorrhage Rate
- Reduced Postprandial Blood Glucose
- Reduced Postprandial Blood Glucose Level
- Reduced Postprandial GLP-1 Level
- Reduced Postprandial Glucose
- Reduced Postprandial Glycemic Response
- Reduced Postprandial Insulin
- Reduced Postprandial Insulin Response
- Reduced Pre-Eclampsia Development
- Reduced Pre-eclampsia
- Reduced Pre-eclampsia Incidence
- Reduced Pre-eclampsia or Pregnancy Loss
- Reduced Preeclampsia Development
- Reduced Pregnancy Disorder Risk
- Reduced Preterm Birth
- Reduced Preterm Birth Rate
- Reduced Preterm Births
- Reduced Prevalence of Gestational Diabetes Mellitus
- Reduced Rate of Preterm Births Under 34 Weeks
- Reduced Risk of Infant Health Problems
- Reduced Risk of Preeclampsia
- Reduced Risk of Pregnancy Complications
- Reduced Risk of Small-for-Gestational-Age Birth
- Reduced Small-for-Gestational-Age
- Reduced Stillbirth
- Reduced Stillbirth or Fetal Death
- Reduced Taurodeoxycholic Acid in Women with GDM
- Reduced Time to Regain Birth Weight
- Reduced Two-Hour Postprandial Glucose
- Reduced Visfatin Level
- Regulated Blood Glucose Levels
- Safety During Pregnancy
- Stabilized Blood Glucose Level
- Stabilized Hemoglobin A1c Level
- Successful Pregnancy Outcome
- Tolerability of Probiotics in Pregnancy
- Unchanged Gestational Glycemia
- Unchanged Glycemic Control
- Unchanged Insulin Resistance
- Unchanged Waist-to-Hip Ratio